Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bojan Lalovic

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Neurotoxicology and Teratology|March 17, 2004
Chronic maternal methanol inhalation in nonhuman primates (Macaca fascicularis): exposure and toxicokinetics prior to and during pregnancyThomas M Burbacher, Danny D Shen, Bojan Lalovic, et al.
Clinical Pharmacology in Drug Development|January 17, 2021
Evaluation of the CYP3A and CYP2B6 Drug-Drug Interaction Potential of LemborexantIshani Landry, Jagadeesh Aluri, Kenya Nakai, et al.
CPT: Pharmacometrics & Systems Pharmacology|March 26, 2024
Population pharmacokinetic-pharmacodynamic modeling of serum biomarkers as predictors of tumor dynamics following lenvatinib treatment in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC)Oneeb Majid, Seiichi Hayato, Sree Harsha Sreerama Reddy, et al.
CPT: Pharmacometrics & Systems Pharmacology|August 29, 2024
Population pharmacokinetics and exposure-response analyses of safety (ARIA-E and isolated ARIA-H) of lecanemab in subjects with early Alzheimer's diseaseOneeb Majid, Youfang Cao, Brian A Willis, et al.
Clinical Pharmacology and Therapeutics|February 21, 2023
Opportunities and Challenges of Disease Progression Modeling in Drug Development - An IQ PerspectiveKosalaram Goteti, Nathan Hanan, Mindy Magee, et al.
The Journal of Allergy and Clinical Immunology|March 15, 2015
Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trialJames G Krueger, Laura K Ferris, Alan Menter, et al.
The Journal of Allergy and Clinical Immunology|December 23, 2018
Psoriatic skin molecular and histopathologic profiles after treatment with risankizumab versus ustekinumabSudha Visvanathan, Patrick Baum, Richard Vinisko, et al.
Clinical Pharmacology and Therapeutics|October 17, 2021
Risk-Based Pharmacokinetic and Drug-Drug Interaction Characterization of Antibody-Drug Conjugates in Oncology Clinical Development: An International Consortium for Innovation and Quality in Pharmaceutical Development PerspectiveChunze Li, Rajeev Menon, Markus Walles, et al.
Lancet (London, England)|April 17, 2017
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 studyBrian G Feagan, William J Sandborn, Geert D'Haens, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Neurotoxicology and Teratology|March 17, 2004
Chronic maternal methanol inhalation in nonhuman primates (Macaca fascicularis): exposure and toxicokinetics prior to and during pregnancyThomas M Burbacher, Danny D Shen, Bojan Lalovic, et al.
Clinical Pharmacology in Drug Development|January 17, 2021
Evaluation of the CYP3A and CYP2B6 Drug-Drug Interaction Potential of LemborexantIshani Landry, Jagadeesh Aluri, Kenya Nakai, et al.
CPT: Pharmacometrics & Systems Pharmacology|March 26, 2024
Population pharmacokinetic-pharmacodynamic modeling of serum biomarkers as predictors of tumor dynamics following lenvatinib treatment in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC)Oneeb Majid, Seiichi Hayato, Sree Harsha Sreerama Reddy, et al.
CPT: Pharmacometrics & Systems Pharmacology|August 29, 2024
Population pharmacokinetics and exposure-response analyses of safety (ARIA-E and isolated ARIA-H) of lecanemab in subjects with early Alzheimer's diseaseOneeb Majid, Youfang Cao, Brian A Willis, et al.
Clinical Pharmacology and Therapeutics|February 21, 2023
Opportunities and Challenges of Disease Progression Modeling in Drug Development - An IQ PerspectiveKosalaram Goteti, Nathan Hanan, Mindy Magee, et al.
The Journal of Allergy and Clinical Immunology|March 15, 2015
Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trialJames G Krueger, Laura K Ferris, Alan Menter, et al.
The Journal of Allergy and Clinical Immunology|December 23, 2018
Psoriatic skin molecular and histopathologic profiles after treatment with risankizumab versus ustekinumabSudha Visvanathan, Patrick Baum, Richard Vinisko, et al.
Clinical Pharmacology and Therapeutics|October 17, 2021
Risk-Based Pharmacokinetic and Drug-Drug Interaction Characterization of Antibody-Drug Conjugates in Oncology Clinical Development: An International Consortium for Innovation and Quality in Pharmaceutical Development PerspectiveChunze Li, Rajeev Menon, Markus Walles, et al.
Lancet (London, England)|April 17, 2017
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 studyBrian G Feagan, William J Sandborn, Geert D'Haens, et al.
Pageof 2